First Horizon Advisors’s Myriad Genetics MYGN Stock Holding History

First Horizon Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-38	Closed	-$337	–	2434
2025 Q1	$337	Hold	38	–	–	﹤0.01%	2259
2024 Q4	$520	Hold	38	–	–	﹤0.01%	2187
2024 Q3	$1.04K	Buy	+38	New	+$1.03K	﹤0.01%	2132
2024 Q1	–	Sell	-1,175	Closed	-$22.5K	–	2356
2023 Q4	$22.5K	Hold	1,175	–	–	﹤0.01%	1293
2023 Q3	$18.8K	Hold	1,175	–	–	﹤0.01%	1273
2023 Q2	$27.2K	Hold	1,175	–	–	﹤0.01%	1150
2023 Q1	$27.3K	Hold	1,175	–	–	﹤0.01%	1152
2022 Q4	$17K	Hold	1,175	–	–	﹤0.01%	1308
2022 Q3	$22K	Sell	1,175 -2,015	-63%	-$46.2K	﹤0.01%	1201
2022 Q2	$57K	Buy	+3,190	New	+$66.2K	﹤0.01%	884
2021 Q4	–	Sell	-27	Closed	–	–	2368
2021 Q3	$0	Buy	+27	New	+$897	﹤0.01%	2375
2015 Q2	–	Sell	-44	Closed	-$1K	–	1466
2015 Q1	$1K	Hold	44	–	–	﹤0.01%	1445
2014 Q4	$1K	Sell	44 -80	-65%	-$2.84K	﹤0.01%	1423
2014 Q3	$4K	Hold	124	–	–	﹤0.01%	1289
2014 Q2	$4K	Buy	+124	New	+$4.61K	﹤0.01%	1272

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

First Horizon Advisors's MYGN Position: Q2 2025 in Review

First Horizon Advisors sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 38 shares — an estimated $337 sold.

First Horizon Advisors first reported a position in MYGN in Q2 2014 and held it in 15 quarters. The position peaked at $57K in Q2 2022. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

First Horizon Advisors reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
First Horizon Advisors sold 38 Myriad Genetics shares in Q2 2025, an estimated $337.
First Horizon Advisors first reported a position in Myriad Genetics in Q2 2014 and held it in 15 quarters.
First Horizon Advisors's Myriad Genetics position peaked at $57K in Q2 2022.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.